Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lexaria Bioscience Corp (NQ: LEXX ) 3.150 +0.060 (+1.94%) Streaming Delayed Price Updated: 11:36 AM EDT, Jul 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Lexaria Bioscience Corp < Previous 1 2 ... 16 17 18 19 20 21 22 23 Next > Lexaria's DehydraTECH Significantly Enhances Delivery of Colchicine in Study VIRAL-A20-3 July 21, 2021 Possible Benefits for Treating SARS-CoV-2/COVID-19 and mRNA Vaccine Side Effects KELOWNA, BC / ACCESSWIRE / July 21, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... From Lexaria Bioscience Corp. Via AccessWire Topics Animal Testing Intellectual Property Exposures Animal Testing COVID-19 Intellectual Property CannabisNewsBreaks – Why Lexaria Bioscience Corp. (NASDAQ: LEXX) Is ‘One to Watch’ July 20, 2021 Via CannabisNewsWire New Patent Expands Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Suite to 20 Granted Worldwide (First in Japan) July 16, 2021 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Completes Successful Antiviral Drug Molecular Characterization Study With Canada's National Research Council July 15, 2021 VIRAL-MC21-1 Demonstrates Stability of DehydraTECH™-Enabled Antiviral Drugs KELOWNA, BC / ACCESSWIRE / July 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"),... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Considerable IP Portfolio with Patent Protection in Japan July 13, 2021 Via CannabisNewsWire Topics Intellectual Property Exposures Intellectual Property Lexaria Receives Patent Protection in Japan July 13, 2021 New patent granted in Japan adds to existing patents in the EU, the U.S., India and Australia KELOWNA, BC / ACCESSWIRE / July 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. (NASDAQ: LEXX) Delists from CSE to Focus Efforts on Most Effective Drug Platform Outcomes July 12, 2021 Via CannabisNewsWire Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Positive Results From its Recent Animal Study on the Effectiveness of its DehydraTECH Drug Delivery Technology July 08, 2021 Via CannabisNewsWire Lexaria Announces Voluntary Delisting from the Canadian Securities Exchange to Concentrate Trading on the Nasdaq Capital Markets July 05, 2021 KELOWNA, BC / ACCESSWIRE / July 5, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that on... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Lexaria Announces 2021 Annual Meeting Results June 29, 2021 KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM) June 17, 2021 Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. Via NewMediaWire Exposures COVID-19 Product Safety Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM) June 17, 2021 New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a... Via Newsfile Exposures COVID-19 Product Safety Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs June 15, 2021 DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Lexaria Provides Progress Report on Six R&D Programs June 09, 2021 - All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied... From Lexaria Bioscience Corp. Via AccessWire Topics Animal Testing Intellectual Property Exposures Animal Testing COVID-19 Intellectual Property Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1 June 07, 2021 - Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation -... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus June 03, 2021 KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever May 20, 2021 - New formulation delivers up to 2,708% more CBD into bloodstream* - Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp.... From Lexaria Bioscience Corp. Via AccessWire Topics Animal Testing Intellectual Property Exposures Animal Testing Intellectual Property Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted May 12, 2021 - New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp.... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Lexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day Podcast May 07, 2021 Phoenix, Arizona--(Newsfile Corp. - May 7, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) ("the Company"),... Via Newsfile Topics Intellectual Property Exposures Intellectual Property Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET May 07, 2021 Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE /... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1 May 06, 2021 - Up to 2,178% more CBD delivered into bloodstream* - Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property BTV Explores Investment Options in Life Sciences May 06, 2021 Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - On national TV Sat. May 8 & Sun. May 9, 2021... Via Newsfile Exposures COVID-19 Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip Video April 27, 2021 Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX) - Chris Bunka,... Via Newsfile Lexaria Commences Human Clinical Hypertension Study April 22, 2021 - Study to examine DehydraTECHTM CBD's ability to control blood pressure - First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC /... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants April 15, 2021 KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Exposures Intellectual Property Lexaria's DehydraTECHTM Technology Utilized in Amari's "Everyday Calm," Named a Top CBD Product Pick by New Hope Network April 14, 2021 - DehydraTECHTM Powers Amari's Award-Winning Products KELOWNA, BC / ACCESSWIRE / April 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global... From Lexaria Bioscience Corp. Via AccessWire Topics Intellectual Property Supply Chain Exposures Intellectual Property Supply Chain Lexaria Is Expanding CBD Use Beyond Medical Applications into $2.65 Billion Marketplace April 08, 2021 New York, New York--(Newsfile Corp. - April 8, 2021) - PCG Digital -- The team at Lexaria Bioscience (NASDAQ: LEXX),... Via Newsfile Topics Cannabis Intellectual Property Exposures COVID-19 Cannabis Intellectual Property < Previous 1 2 ... 16 17 18 19 20 21 22 23 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.